Eliquis to face generic competition in late 2026? Bristol Myers Squibb (BMS) and Pfizer’s oral blood thinner – Eliquis® (Apixaban) was approved in the United
Maximizing Innovation Lifespans: Canada Patent Term Adjustment To commit to Canada-European Union Comprehensive Economic and Trade Agreement (CETA), Canada introduced Certificate of Supplementary Protection
Preventing Delays in Generic Drug Entry Generic drugs are identical to their brand-name counterparts in safety, effectiveness, strength, and quality. Also, they offer the same therapeutic
Patent Term Extensions – A Lifeline to the Pharmaceutical Innovation 1. What are Patent Term Extensions? How do they differ from Supplementary Protection Certificates?
